Valuation: Paion AG

Market Cap 144K 162K 135K 122K 231K 15.65M 233K 1.62M 630K 7.98M 609K 596K 25.66M P/E 2021
-3.89x
P/E 2022 -53x
Enterprise Value 9.87M 11.12M 9.23M 8.37M 15.81M 1.07B 15.92M 111M 43.13M 547M 41.72M 40.83M 1.76B EV / Sales 2021
14.1x
EV / Sales 2022 1.22x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 day-85.71%
1 week-85.71%
Current month-85.71%
1 month-85.71%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.01
0.01
Current year 0.01
Extreme 0.01
0.07
1 year 0.01
Extreme 0.01
0.07
3 years 0
Extreme 0.0001
0.38
5 years 0
Extreme 0.0001
20.8
10 years 0
Extreme 0.0001
36
Manager TitleAgeSince
Chief Executive Officer 62 01/09/2023
Director of Finance/CFO - 01/06/2022
Director TitleAgeSince
Director/Board Member 65 01/10/2012
Director/Board Member 75 01/06/2017
Director/Board Member - 22/05/2019
Change 5-day change 1-year change 3-year change Capi.($)
-85.71%-85.71% - - 412K
+4.16%+3.42%+49.37%+94.17% 74.31B
+2.76%-1.60%+22.80%+78.53% 56.95B
+0.24%-1.34%+3.41%+34.31% 48.3B
-3.89%-2.37%+328.60%+697.28% 44.51B
-0.95%-2.04%+28.53%+32.66% 43.8B
+1.11%+0.06%+6.08%+110.19% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.55%-2.39%-8.51%-13.49% 24.53B
Average -7.94%-0.20%+52.97%+125.26% 43.73B
Weighted average by Cap. +1.01%-0.50%+56.95%+133.73%

Financials

2021 2022
Net sales 7.13M 8.03M 6.67M 6.05M 11.42M 774M 11.5M 80.12M 31.16M 395M 30.14M 29.5M 1.27B 33.25M 37.45M 31.11M 28.2M 53.26M 3.61B 53.65M 374M 145M 1.84B 141M 138M 5.92B
Net income -21.79M -24.54M -20.39M -18.48M -34.9M -2.37B -35.15M -245M -95.24M -1.21B -92.12M -90.14M -3.88B -579K -652K -542K -491K -928K -62.88M -934K -6.51M -2.53M -32.08M -2.45M -2.4M -103M
Net Debt 13.77M 15.51M 12.89M 11.68M 22.06M 1.5B 22.22M 155M 60.19M 763M 58.22M 56.97M 2.45B 9.72M 10.95M 9.1M 8.25M 15.58M 1.06B 15.69M 109M 42.5M 539M 41.11M 40.23M 1.73B
Logo Paion AG
Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Employees
64
Date Price Change Volume